OrthoTrophix, Inc   Report issue

For profit Phase 2
Founded: Oakland CA United States (2011)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2014
NCT01925261
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

tpx-100 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1